XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2023
Feb. 28, 2019
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement     $ 48,926,000 $ 43,660,000 $ 86,573,000 $ 82,280,000  
Deferred revenue     108,812,000   108,812,000   $ 122,714,000
Medicare Reimbursements              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement     1,300,000 1,400,000 2,700,000 2,800,000  
Medicare Reimbursements | Immune Medicine Service Revenue              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement         400,000 200,000  
Medicare Reimbursements | MRD Service Revenue              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement         2,300,000 2,600,000  
MRD Development Agreements | Maximum              
Disaggregation Of Revenue [Line Items]              
Additional milestone payment receivable     399,500,000   399,500,000    
Genentech Collaboration Agreement              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement $ 7,700,000   17,500,000 $ 13,800,000 26,700,000 $ 26,000,000  
Non-refundable upfront payments received   $ 300,000,000.0     $ 300,000,000.0    
Additional transaction price of regulatory milestone 10,000,000            
Deferred revenue $ 2,300,000            
Genentech Collaboration Agreement | Regulatory Milestones              
Disaggregation Of Revenue [Line Items]              
Additional transaction price of regulatory milestone     10,000,000.0        
Genentech Collaboration Agreement | Maximum              
Disaggregation Of Revenue [Line Items]              
Revenue recognition expected period         9 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     75,000,000.0   $ 75,000,000.0    
Genentech Collaboration Agreement | Maximum | Development Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     300,000,000.0   300,000,000.0    
Genentech Collaboration Agreement | Maximum | Commercial Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     1,430,000,000   1,430,000,000    
Genentech Collaboration Agreement | Minimum              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     $ 1,800,000,000   $ 1,800,000,000    
Revenue recognition expected period         8 years